Holen Sie sich die Stockscreener-App
2.14
2.39%
0.05
Handel nachbörslich:
2.16
0.02
+0.93%
Schlusskurs vom Vortag:
$2.09
Offen:
$2.1
24-Stunden-Volumen:
28,776
Relative Volume:
1.39
Marktkapitalisierung:
$3.47M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-36.46M
KGV:
-13.38
EPS:
-0.16
Netto-Cashflow:
$-30.20M
1W Leistung:
+1.90%
1M Leistung:
-5.31%
6M Leistung:
-81.55%
1J Leistung:
-78.83%
1-Tages-Spanne:
$2.10
$2.29
1-Wochen-Bereich:
$2.0735
$2.86
52-Wochen-Spanne:
$1.95
$32.85
Alaunos Therapeutics Inc Stock (TCRT) Company Profile
Firmenname
Alaunos Therapeutics Inc
Sektor
Branche
Telefon
(346) 355-4099
Adresse
2617 BISSONNET ST, HOUSTON
Vergleichen Sie TCRT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| TCRT | 2.14 | 3.47M | 0 | -36.46M | -30.20M | -0.16 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
Alaunos Therapeutics Inc Aktie (TCRT) Neueste Nachrichten
Alaunos Therapeutics Inc (TCRT) Quarterly 10-Q Report - Quartzy
Ziopharm: Q3 Earnings Snapshot - The Washington Post
TCRT Stock Touches 52-Week Low at $1.96 Amid Market Challenges - Investing.com
TCRT stock touches 52-week low at $2.06 amid market challenges - Investing.com
Intracranial Therapeutic Market Rewriting its Growth Cycle |Novartis AG, BioMarin, CORESTEM Inc., Alaunos Therapeutics, – IndiaPolitics.com - IndiaPolitics.com
After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen - Fierce Biotech
Alaunos Therapeutics ends key agreement and updates on financial condition By Investing.com - Investing.com Australia
Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy - Yahoo Finance
Precigen reclaims rights after terminating license agreement - Investing.com India
Precigen Terminates License Agreement With Alaunos Therapeutics - MarketWatch
Alaunos Therapeutics ends key agreement and updates on financial condition - Investing.com
AskBio and Belief BioMed partner to advance gene therapies - Pharmaceutical Technology
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
An Analysis of Atricure Inc (ATRC)’s Potential Price Growth - Knox Daily
Applied Therapeutics Surges on Positive FDA Update for Govorestat - BP Journal
Applied Therapeutics jumps as US FDA cancels panel meeting for genetic disorder drug - XM
Gene Switch / Molecular Switch Market Set to Reach USD 1.44 Billion by 2031 with 9.9% CAGR - WhaTech
Daily Market Movement: Atricure Inc (ATRC) Sees a -3.23 Decrease, Closing at 27.30 - The Dwinnex
Aptevo Therapeutics announces $3.0M offering priced at-the-market - TipRanks
Check out these key findings about Atricure Inc (ATRC) - SETE News
Atmos Energy Co. (NYSE:ATO) Shares Sold by Prudential PLC - MarketBeat
Gilead and Genesis partner to create novel therapies using AI - Pharmaceutical Technology
Navigator gains $100m in Series A funding for antibody therapeutics - Pharmaceutical Technology
VION Biosciences acquires Echelon Biosciences - Pharmaceutical Technology
TCRT stock touches 52-week low at $2.28 amid market challenges - Investing.com India
Ziopharm: Q2 Earnings Snapshot - San Antonio Express-News
Eli Lilly inaugurates R&D facility in Boston, US - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Trading Down 4.2% - Defense World
Genentech and Sangamo to develop neurodegenerative disease therapies - Pharmaceutical Technology
TCRT stock touches 52-week low at $3.57 amid market challenges - Investing.com Nigeria
Alaunos Therapeutics announces 1-for-10 reverse stock split By Investing.com - Investing.com Australia
Alaunos Therapeutics announces 1-for-10 reverse stock split - Investing.com
XyloCor taps SmartWise’s infusion device for gene therapy administration - Clinical Trials Arena
Intracranial Therapeutic Industry Startegy Analysis} Novartis AG, BioMarin, CORESTEM Inc., Alaunos Therapeutics ... - Economica
Alaunos (TCRT) Dips More Than Broader Markets: What You Should Know - Yahoo New Zealand News
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings ... - Yahoo Lifestyle UK
Alaunos Therapeutics appoints new accounting firmInvesting.com ZA - Investing.com South Africa
Alaunos Therapeutics appoints new accounting firm By Investing.com - Investing.com
Ziopharm Oncology to Participate in Upcoming Conferences - Quantisnow
Ziopharm Oncology to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast on February 25 ... - Quantisnow
Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations - Quantisnow
New Strong Buy Stocks for November 18th - Yahoo Movies Canada
Commerce Bank Decreases Stock Position in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) - Defense World
The past five years for Alaunos Therapeutics (NASDAQ:TCRT) investors has not been profitable - Yahoo News Australia
Quarterly Metrics: Quick and Current Ratios for Alaunos Therapeutics Inc (TCRT) – DWinneX - The Dwinnex
Turn Bio and HanAll to develop therapies for age-related conditions - Pharmaceutical Technology
Alaunos Therapeutics Reports First Quarter 2023 Financial Results - br.ADVFN.com
AltruBio secures $225m for immune checkpoint programme development - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Trading Down 3.6% - Defense World
Alaunos Therapeutics (NASDAQ:TCRT) investors are sitting on a loss of 78% if they invested three years ago - Yahoo Lifestyle UK
Finanzdaten der Alaunos Therapeutics Inc-Aktie (TCRT)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):